Zobrazeno 1 - 2
of 2
pro vyhledávání: '"14(3)"'
Autor:
Wouter Dercksen, Dinja T. Kruger, Agnes Jager, Inge R. H. M. Konings, John W.M. Martens, Maurice P.H.M. Jansen, Jamal Oulad Hadj, Stefan Sleijfer, Epie Boven
Publikováno v:
Molecular Oncology, Vol 14, Iss 3, Pp 490-503 (2020)
Molecular Oncology, 14, 490-503. John Wiley & Sons Ltd.
Kruger, D T, Jansen, M P H M, Konings, I R H M, Dercksen, W M, Jager, A, Oulad Hadj, J, Sleijfer, S, Martens, J W M & Boven, E 2020, ' High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2-postmenopausal breast cancer patients treated with everolimus and exemestane ', Molecular oncology, vol. 14, no. 3, pp. 490-503 . https://doi.org/10.1002/1878-0261.12617
Molecular Oncology
Molecular oncology, 14(3), 490-503. Elsevier
Molecular Oncology, 14, 490-503. John Wiley & Sons Ltd.
Kruger, D T, Jansen, M P H M, Konings, I R H M, Dercksen, W M, Jager, A, Oulad Hadj, J, Sleijfer, S, Martens, J W M & Boven, E 2020, ' High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2-postmenopausal breast cancer patients treated with everolimus and exemestane ', Molecular oncology, vol. 14, no. 3, pp. 490-503 . https://doi.org/10.1002/1878-0261.12617
Molecular Oncology
Molecular oncology, 14(3), 490-503. Elsevier
We determined whether progression-free survival (PFS) in metastatic breast cancer (MBC) patients receiving everolimus plus exemestane (EVE/EXE) varies depending on circulating tumour DNA (ctDNA) characteristics. Baseline plasma cell-free DNA (cfDNA)
Autor:
Paul van der Leest, Ed Schuuring
Publikováno v:
Molecular oncology, 14(3), 487-489. Wiley
Molecular Oncology
Molecular Oncology, Vol 14, Iss 3, Pp 487-489 (2020)
Molecular Oncology
Molecular Oncology, Vol 14, Iss 3, Pp 487-489 (2020)
We determined whether progression‐free survival (PFS) in metastatic breast cancer (MBC) patients receiving everolimus plus exemestane (EVE/EXE) varies depending on circulating tumour DNA (ctDNA) characteristics. Baseline plasma cell‐free DNA (cfD